Abstract Number: 2587 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Background/Purpose: Proteasome inhibition is a standard of care for plasma cell malignancies. The first-generation inhibitor, bortezomib (BTZ), targets the constitutive proteasome and immunoproteasome and has…Abstract Number: 2588 • 2017 ACR/ARHP Annual Meeting
Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Background/Purpose: The guideline or recommendation for lupus nephritis (LN) has been recently established by both ACR and EULAR, and hydroxychloriquine (HCQ) is recommended for all…Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…Abstract Number: 2590 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Background/Purpose : Organ manifestation domain score improvement was assessed with subcutaneous (SC) belimumab (BEL) plus standard SLE care (SoC) in active, autoantibody-positive SLE. Methods: BLISS-SC…Abstract Number: 2591 • 2017 ACR/ARHP Annual Meeting
Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
Background/Purpose: Studies have demonstrated an association between smoking and more severe cutaneous lupus erythematosus, resulting in decreased health-related quality of life and treatment response.1 We…Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…Abstract Number: 2593 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. Methods: Retrospective…Abstract Number: 2594 • 2017 ACR/ARHP Annual Meeting
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard…Abstract Number: 2595 • 2017 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Background/Purpose: To evaluate the change in ANA titers as a proxy for progression in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxychloroquine (HCQ)…Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…Abstract Number: 2597 • 2017 ACR/ARHP Annual Meeting
Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
Background/Purpose: Even if randomized trials EXPLORER and LUNAR failed to prove the superiority of rituximab versus placebo in patients with systemic lupus erythematosus, several encouraging…Abstract Number: 2598 • 2017 ACR/ARHP Annual Meeting
The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
Background/Purpose: Exercise and psychological stress have been shown to produce opposite effects on immunomodulation. Prior studies in patients with Systemic Lupus Erythematosus (SLE) have demonstrated…Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
ACR Meeting Abstracts